2025 Q3 -tulosraportti
87 päivää sitten54 min
3,75 DKK/osake
Viimeisin osinko
3,15%Tuotto/v
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
2 432 651
Myynti
Määrä
2 429 737
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 125 | - | - | ||
| 689 | - | - | ||
| 16 | - | - | ||
| 228 | - | - | ||
| 449 | - | - |
Ylin
377,65VWAP
Alin
366,45VaihtoMäärä
2 264,2 6 104 675
VWAP
Ylin
377,65Alin
366,45VaihtoMäärä
2 264,2 6 104 675
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 5.2. 4 päivää |
| Menneet tapahtumat | ||
|---|---|---|
| Ylimääräinen yhtiökokous 2025 | 14.11.2025 | |
| 2025 Q3 -tulosraportti | 6.11.2025 | |
| 2025 Q2 -tulosraportti | 7.8.2025 | |
| 2025 Q1 -tulosraportti | 8.5.2025 | |
| Vuosittainen yhtiökokous 2025 | 27.3.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·9 min sitten · MuokattuI actually believe that NN will deliver an OK financial report next week and also see that they can have a very exciting 2026. My biggest fear is how the management, especially Karsten Knudsen, can turn “the glass is half full” into “the glass is half empty”. It's thought-provoking that the management's communication to the market should be the biggest concern!
·14 t sittenWhat are the expectations for the earnings report?
·14 t sittenI honestly think Novo looks historically cheap compared to the quality and structural growth the company is currently experiencing. Wegovy and the rest of the GLP-1 portfolio have already proven both demand, treatment loyalty, and pricing power, while production capacity continues to scale up. What truly makes the case interesting for me is the pipeline. CagriSema addresses some of the clear limitations of current treatments, especially in non-responders, and could become an important next step in obesity treatment. Amycretin looks even more exciting as a potential technological leap with the possibility of higher weight loss and better flexibility in administration. Together, they reduce dependence on Wegovy and extend Novo's leading position for several years to come. At the same time, the global obesity market is still early in its development. With possible indication expansions within cardiovascular disease, NASH, and other metabolic comorbidities, I see significant long-term upside. When I combine the high visibility of cash flows, the strong balance sheet, and the research advantage with the current valuation, I find it hard to see the current level as anything other than attractive in the long term.
·12 t sittenThe pill also only constitutes “30” percent of the market, it is estimated.
·15 t sittenThe following was written here: NN cannot go below 400 again (the price then slightly over 400). I wrote: It's extremely dangerous to enter this one, it can very well go down to the 350-level again. WHO was right?
·17 t sitten · MuokattuLooking technically at the price and RSI, it indicates a bull case, however, no one knows what the upcoming earnings report will say, it could be bearish. Explanation: on the 4H chart, it is seen that on 15/1 and 30/1, the price is approximately the same at the bottom level, but RSI is significantly lower on 30/1 = bullish. The price on 12/1 and 23/1, here the price is higher on 23/1, but RSI is lower than on 12/1 = bullish. Looking at the 1-2 hour chart, Novo is oversold = bullish. Dollar USDX is oversold, so it looks like it will rise = bullish. seen better on Tradingview. This is a technical observation and not a recommendation, I own Novo myself.. Good luck to Novo owners.
·17 t sittenTry the same with other dates in 2025 with the same parameters and see what happened? It's fine that you're trying to convince yourself that Novo is an okay stock and even in a Bull scenario, but it's unusable! Of course, it's not a recommendation, that pretty much goes without saying.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
87 päivää sitten54 min
3,75 DKK/osake
Viimeisin osinko
3,15%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·9 min sitten · MuokattuI actually believe that NN will deliver an OK financial report next week and also see that they can have a very exciting 2026. My biggest fear is how the management, especially Karsten Knudsen, can turn “the glass is half full” into “the glass is half empty”. It's thought-provoking that the management's communication to the market should be the biggest concern!
- ·14 t sittenWhat are the expectations for the earnings report?
- ·14 t sittenI honestly think Novo looks historically cheap compared to the quality and structural growth the company is currently experiencing. Wegovy and the rest of the GLP-1 portfolio have already proven both demand, treatment loyalty, and pricing power, while production capacity continues to scale up. What truly makes the case interesting for me is the pipeline. CagriSema addresses some of the clear limitations of current treatments, especially in non-responders, and could become an important next step in obesity treatment. Amycretin looks even more exciting as a potential technological leap with the possibility of higher weight loss and better flexibility in administration. Together, they reduce dependence on Wegovy and extend Novo's leading position for several years to come. At the same time, the global obesity market is still early in its development. With possible indication expansions within cardiovascular disease, NASH, and other metabolic comorbidities, I see significant long-term upside. When I combine the high visibility of cash flows, the strong balance sheet, and the research advantage with the current valuation, I find it hard to see the current level as anything other than attractive in the long term.·12 t sittenThe pill also only constitutes “30” percent of the market, it is estimated.
- ·15 t sittenThe following was written here: NN cannot go below 400 again (the price then slightly over 400). I wrote: It's extremely dangerous to enter this one, it can very well go down to the 350-level again. WHO was right?
- ·17 t sitten · MuokattuLooking technically at the price and RSI, it indicates a bull case, however, no one knows what the upcoming earnings report will say, it could be bearish. Explanation: on the 4H chart, it is seen that on 15/1 and 30/1, the price is approximately the same at the bottom level, but RSI is significantly lower on 30/1 = bullish. The price on 12/1 and 23/1, here the price is higher on 23/1, but RSI is lower than on 12/1 = bullish. Looking at the 1-2 hour chart, Novo is oversold = bullish. Dollar USDX is oversold, so it looks like it will rise = bullish. seen better on Tradingview. This is a technical observation and not a recommendation, I own Novo myself.. Good luck to Novo owners.·17 t sittenTry the same with other dates in 2025 with the same parameters and see what happened? It's fine that you're trying to convince yourself that Novo is an okay stock and even in a Bull scenario, but it's unusable! Of course, it's not a recommendation, that pretty much goes without saying.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
2 432 651
Myynti
Määrä
2 429 737
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 125 | - | - | ||
| 689 | - | - | ||
| 16 | - | - | ||
| 228 | - | - | ||
| 449 | - | - |
Ylin
377,65VWAP
Alin
366,45VaihtoMäärä
2 264,2 6 104 675
VWAP
Ylin
377,65Alin
366,45VaihtoMäärä
2 264,2 6 104 675
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 5.2. 4 päivää |
| Menneet tapahtumat | ||
|---|---|---|
| Ylimääräinen yhtiökokous 2025 | 14.11.2025 | |
| 2025 Q3 -tulosraportti | 6.11.2025 | |
| 2025 Q2 -tulosraportti | 7.8.2025 | |
| 2025 Q1 -tulosraportti | 8.5.2025 | |
| Vuosittainen yhtiökokous 2025 | 27.3.2025 |
2025 Q3 -tulosraportti
87 päivää sitten54 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 5.2. 4 päivää |
| Menneet tapahtumat | ||
|---|---|---|
| Ylimääräinen yhtiökokous 2025 | 14.11.2025 | |
| 2025 Q3 -tulosraportti | 6.11.2025 | |
| 2025 Q2 -tulosraportti | 7.8.2025 | |
| 2025 Q1 -tulosraportti | 8.5.2025 | |
| Vuosittainen yhtiökokous 2025 | 27.3.2025 |
3,75 DKK/osake
Viimeisin osinko
3,15%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·9 min sitten · MuokattuI actually believe that NN will deliver an OK financial report next week and also see that they can have a very exciting 2026. My biggest fear is how the management, especially Karsten Knudsen, can turn “the glass is half full” into “the glass is half empty”. It's thought-provoking that the management's communication to the market should be the biggest concern!
- ·14 t sittenWhat are the expectations for the earnings report?
- ·14 t sittenI honestly think Novo looks historically cheap compared to the quality and structural growth the company is currently experiencing. Wegovy and the rest of the GLP-1 portfolio have already proven both demand, treatment loyalty, and pricing power, while production capacity continues to scale up. What truly makes the case interesting for me is the pipeline. CagriSema addresses some of the clear limitations of current treatments, especially in non-responders, and could become an important next step in obesity treatment. Amycretin looks even more exciting as a potential technological leap with the possibility of higher weight loss and better flexibility in administration. Together, they reduce dependence on Wegovy and extend Novo's leading position for several years to come. At the same time, the global obesity market is still early in its development. With possible indication expansions within cardiovascular disease, NASH, and other metabolic comorbidities, I see significant long-term upside. When I combine the high visibility of cash flows, the strong balance sheet, and the research advantage with the current valuation, I find it hard to see the current level as anything other than attractive in the long term.·12 t sittenThe pill also only constitutes “30” percent of the market, it is estimated.
- ·15 t sittenThe following was written here: NN cannot go below 400 again (the price then slightly over 400). I wrote: It's extremely dangerous to enter this one, it can very well go down to the 350-level again. WHO was right?
- ·17 t sitten · MuokattuLooking technically at the price and RSI, it indicates a bull case, however, no one knows what the upcoming earnings report will say, it could be bearish. Explanation: on the 4H chart, it is seen that on 15/1 and 30/1, the price is approximately the same at the bottom level, but RSI is significantly lower on 30/1 = bullish. The price on 12/1 and 23/1, here the price is higher on 23/1, but RSI is lower than on 12/1 = bullish. Looking at the 1-2 hour chart, Novo is oversold = bullish. Dollar USDX is oversold, so it looks like it will rise = bullish. seen better on Tradingview. This is a technical observation and not a recommendation, I own Novo myself.. Good luck to Novo owners.·17 t sittenTry the same with other dates in 2025 with the same parameters and see what happened? It's fine that you're trying to convince yourself that Novo is an okay stock and even in a Bull scenario, but it's unusable! Of course, it's not a recommendation, that pretty much goes without saying.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
2 432 651
Myynti
Määrä
2 429 737
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 125 | - | - | ||
| 689 | - | - | ||
| 16 | - | - | ||
| 228 | - | - | ||
| 449 | - | - |
Ylin
377,65VWAP
Alin
366,45VaihtoMäärä
2 264,2 6 104 675
VWAP
Ylin
377,65Alin
366,45VaihtoMäärä
2 264,2 6 104 675
Välittäjätilasto
Dataa ei löytynyt